Brasil enfrenta aumento alarmante de muertes por COVID-19 en jóvenes menores de 40 años

A 22-year-old man died in São Paulo last week because there was no intensive care bed available for him. He was not elderly, not immunocompromised in any obvious way. He was simply young and unlucky, and the hospital system had run out of space. His death marked a threshold Brazil had not yet crossed—the first documented fatality from sheer lack of capacity, not from the virus itself, but from the collapse around it.

This is the shape of Brazil's pandemic now, in late March 2021. The country that seemed, months ago, to be moving through the crisis like many others has instead become the epicenter of something far worse. More than 307,000 Brazilians have died since the pandemic began, a toll second only to the United States. But what distinguishes Brazil's outbreak now is not just its scale but its character: it is killing the young.

In the first three weeks of March alone, roughly 2,800 Brazilians under 40 died of COVID-19. That is more than double the number who died in the same window in February, and nearly triple the toll from January. The shift is visible in the hospitals themselves. Dr. Jaques Sztajnbok, who oversees the intensive care unit at Emilio Ribas Hospital in São Paulo, describes seeing patients without underlying conditions, young and previously healthy, arriving with severe respiratory failure. "We are seeing a prevalence of younger patients, without comorbidities, admitted with very serious presentations," he said. "It appears to be a frequent situation across all the ICUs in Brazil." The proportion of deaths among those under 40 has crept upward—from less than 5 percent of all COVID deaths in February to around 6 percent in March. More strikingly, deaths among Brazilians aged 30 to 59 have climbed from 20 percent of the total in December to nearly 27 percent now.

The hospitals are filling with younger patients than they were a year ago. At Emilio Ribas, half of those currently hospitalized are under 60; twelve months earlier, that figure was 35 percent. The shift has consequences. Younger patients, their bodies more resilient, stay longer—ICU stays have nearly doubled from an average of 15 days to 28 days. The system, already strained, is being pressed harder by people who linger.

Experts point to a single cause: the P.1 variant, first identified in the city of Manaus in the Amazon region. This strain appears to be roughly twice as transmissible as earlier versions and capable of reinfecting people who have already had COVID-19—between 25 and 61 percent of previously infected individuals, according to available studies. Manaus itself had been hit so hard in the first wave that some believed the city had achieved herd immunity. When restrictions eased, residents crowded beaches and public spaces. The P.1 variant found fertile ground. When it spread beyond the city, other parts of Brazil welcomed it the same way. In São Paulo state, genetic sequencing suggests the variant accounts for 80 to 90 percent of current cases. A second concerning variant, P.2, has emerged from Rio de Janeiro and is also spreading.

The infrastructure to contain it barely exists. Of Brazil's 27 states, 25 now have ICU occupancy at or above 80 percent. Eighteen states face shortages of neuromuscular blocking agents—drugs essential for patients on ventilators. Six states have dangerously low oxygen supplies. The National Forum of Governors warns of "a collapse within the collapse." The Fiocruz Foundation describes the situation as the "greatest sanitary and hospital crisis" in Brazilian history.

The government's response has been, at best, late. President Jair Bolsonaro has openly opposed lockdowns, mocked those concerned about the virus, and pressured local authorities to lift restrictions. He has cycled through three health ministers since the pandemic began. He promoted unproven treatments, fought the release of data, and delayed vaccine procurement despite offers from manufacturers like Pfizer and Janssen. Only this month did the federal government finally agree to purchase vaccines from Pfizer and Janssen, to complement the AstraZeneca and CoronaVac doses already being administered. Brazil has begun domestic production—Fiocruz has delivered its first locally made AstraZeneca doses, and the Butantan Institute in São Paulo has started manufacturing CoronaVac—but the vaccination campaign remains far behind the scale of the crisis.

Neighboring countries have begun closing their borders. Peru, Colombia, and Argentina have suspended flights from Brazil. Only two of the ten major destinations for Brazilian travelers remain open. The World Health Organization's director general warned that if Brazil does not take the crisis seriously, it will continue to affect the entire region and beyond. The virus that emerged from the Amazon is now a global concern, and Brazil's failure to contain it is everyone's problem.